Amgen buys kidney-disease treatment company, Ilypsa, for $420M
See David Hamilton’s story at VentureBeat Life Sciences.
Next Story: Ultrasound clot-buster Ekos raises $10M in debt
Previous Story: Amgen buys kidney-disease biotech Ilypsa for $420M
About the Author, Matt Marshall
Matt Marshall is editor and CEO of VentureBeat. Follow him on Twitter at @mmarshall, and follow VentureBeat on Twitter at @venturebeat.